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29 Aim of this study was to evaluate the incidence of ceftazidime/avibactam resistance among KPC-
30 producing Klebsiella pneumoniae (KPC-Kp) strnins isolated from patients with bloodstream 
31 infection. 
32 Methods 
33 We collected 120 carbapenemase producing Enterobacteriaceae (CPE) strnins from unique patients 
34 hospitalized in two Italian hospitals between Januaiy 2018 to Febmaiy 2019. Strains were 
35 phenotypically characterized for the type of carbapenemase production and susceptibility to 
36 ceftazidime/avibactam. Ceftazidime/avibactam-resistant strains were chai·acterized by whole-
37 genome sequencmg. 
38 Results 
39 Dm-ing the study period, we characterized 105 (87,5%) KPC producers among a total of 120 CPE 
40 strains. Ceftazidime-avibactam resistance was found in three KPC-Kp strnins isolated from patients 
41 with no histo1y of previous ceftazidime/avibactam-based treatment. Of note, two out of three 
42 ceftazidime-avibactam-resistant KPC-Kp were also resistant to meropenem/vaborbactam. Genomic 
43 chai·acterization showed that a ceftazidime/avibactam-resistant KPC-Kp hai·bored a mixed 
44 population with D179Y mutated KPC-2, while the other two ceftazidime-avibactam-resistant KPC-
45 Kp possessed non-functional ompK35-ompK37 and mutated ompK36 porins associated with higher 
46 copy number of blaKPC gene. 
4 7 Conclusion 
48 Om results showed that incidence of ceftazidime/avibactam resistance emerged in KCP-Kp strains 
49 independently from previous antimicrobial exposme. Resistance to ceftazidime/avibactam was 
50 associated to mutations within blaKPc gene or porins deficiency associated to higher blaKPc copy 
51 number that is also related to the meropenem/vaborbactam resistance. 
52 
53 Introduction 
54 Carbapenemase-producing Enterobacteriaceae (CPE) represent a serious threat for human health 
55 and a serious challenge for clinicians. CPE are often resistant to several antimicrobial agents 
56 commonly used for the treatment of Gram-negative infections. As a consequence, severe infections 
57 due to CPE are associated to high of mortality and morbidity rates [1]. Recently, a novel B-lactam 
58 combination, ceftazidime/avibactam (CAZ/AVI), was approved for treatment of infections due to 
59 Gram-negative bacteria producing class A, class C and class D B-lactamase. Clinical studies 
60 demonstrated that CAZ-AVI therapy exhibited higher rate of clinical success than other 
61 antimicrobial regimens for bloodstream infections (BSis), especially against KPC-producing 
62 Klebsiella pneumoniae (KPC-Kp) bacteremia [2]. Although CAZIA VI-based treatments exhibited 
63 initial promising clinical efficacy for treatment of severe KPC-Kp infections, resistance 
64 development has been recently reported [3-4]. Previous studies showed that development of 
65 resistance often emerged during prolonged CAZ/AVI-based ti·eatment [4-5] and pneumonia and 
66 renal replacement therapy are independent risk factors for microbiological h'eatment failure and the 
67 emergence of resistance [ 6]. CAZI A VI resistance was associated to either different mutations of 
68 KPC enzyme or hyperexpression of blaKPc gene associated with nonfunctional porins [5-8]. 
69 Aim of this study was to evaluated the incidence of ceftazidime/avibactam resistance in KPC-Kp 




74 Between January 2018 and Febmary 2019, we collected all carbapenemase-producing 
75 Enterobacteriaceae (CPE) sti·ains isolated from BSis of patients recovered into two large te1iiaiy 
76 Hospitals in Bologna metropolitan area. The study was conducted in accordance with the 
77 Declai·ation of Helsinki. Sainples were coded and analysis was perfo1med with anonymized 
78 database. Antimicrobial susceptibility testing was perfo1med by Microscan, confomed by MIC test 
79 strip (Liofilchem, Italy), and MIC results were interpreted following EUCAST clinical breakpoints 
80 v9.0. [9]. The types of carbapenemase were detennined with NG-Test CARBA 5 (NG Biotech, 
81 France) and confomed with molecular assay (Xpe1i Carba-R, Cepheid) in doubtful cases. 
82 Ceftazidime/avibactam activity was tested only against confmned KPC-Kp and OXA-48 strains, 
83 excluding KPC and OXA-48 or MBL co-producing strains. Whole-genome sequencing ofKPC-Kp 
84 resistant strains was perfonned to identify the genetic dete1minants responsible of 
85 ceftazidime/avibactam-resistance. Briefly, genomic DNA was sequenced using the Illumina MiSeq 
86 platfo1m (Illumina, San Diego, USA) with a 2x250 paired-end nm and assembled as previously 
87 described [5]. Bacteria genomes were automatically annotated on the RAST server and 
88 antimicrobial resistance genes were investigated against bacterial isolate genome sequence database 
89 (BIGSdb) (http://bigsdb.web.pasteur.fr). Sequence type and allele frequencies was investigated as 
90 previously described [5]. The core genome single nucleotide polymorphism (SNP) phylogeny was 
91 perfo1med as previously described [10]. Relative quantification of blaKPc gene in comparison to 




96 Dm-ing the study period, we isolated 120 CPE strains harbo1111g different types of carbapenemase. 
97 Phenotypic characterization revealed that vast majority (87.5%) were KPC producers, while 10% 
98 were MBL and 2.5% were OXA-48 producers. Among different CPE, K. pneumoniae was the most 
99 common species identified. The KPC-Kp distribution revealed that 53.4% of bacteremic patients 
100 were hospitalized in Intensive Care Units (ICUs), 33.3% in medicine, 5.8% in haemato-oncology, 
101 5% in urgical and 2.5% in transplantation wards. 
102 Antimicrobial susceptibility rates of 105 KPC-Kp strains are shown in Figure SI in the 
103 Supplementaiy material. In vitro activity of ceftazidime-avibactam demonstrated that 102 (97 .1 % ) 
104 out of 105 KPC-Kp strains were susceptible, while 3 (2.9%) isolates were resistant. In detail, 
105 median MIC of ceftazidime/avibactam-susceptible isolates was 2 µg/ml (interqmuiile range, IQR, 
106 1-4), while median MIC for resistant strains was 32 µg/ml (IQR, 16-256) (Figure 1). The
107 ceftazidime/avibactam-resistant KPC-Kp strains were also resistant to carbapenems. 
108 Interestingly, two out of ceftazidime/avibactam-resistant KPC-Kp strnins were also resistant to 
109 meropenem/vaborbactam (Table 1). Retrospective clinical data showed that 43 out of 105 patients 
110 with BSI due KPC-Kp isolates were treated with CAVA VI-based ti·eatment. At the same time, none 
111 of the patients with BSI due to CAZ/AVI-resistant KPC-Kp su-ains received ceftazidime/avibactam 
112 during antimicrobial therapy. CPE rectal screening demonsti·ated that patient with BSI due to 
113 KpBO5 was colonized 19 days before, while the other two patients were not or colonized few days 
114 before BSis (Table 1). 
115 A summary of the genetic characteristics of ceftazidime/avibactam-resistant KPC-producing K.
116 pneumoniae sti·ains are shown in Table 1. Genetic analysis demonsti·ated that all KPC-Kp sti·ains 
117 belonged to the Clonal Complex (CC) 258, harbored the same genes coding for antimicrobial 
118 resistance to fluoroquinolone and sulfonamide, while differed for genes responsible for 
119 aminoglycoside resistance. Analysis of genetic detenninants responsible for B-lactam resistance 
120 showed that KPC-Kp sti·ains harbored different B-lactamase gene patterns. Of note, two out of three 
121 ceftazidime/avibactam-resistant KPC-Kp sti·ains harbored a wild-type blaKPc-3 gene, while KpBO5 
122 canied a SNP (i.e. 537 G>T) within blaKPc-2 genes, which detennined an amino acid substitution at 
123 position 179 (Dl 79Y). In detail, reads alignment against blaKPc-2 gene revealed that KpBO5 
124 genome had a mutant allele frequency of 45.7%. Genetic environment of blaKPc gene demonstrated 
125 that all three KPC-Kp sti·ains harbored Tn4401 isofo1m a. 
126 Analysis of outer membrane porin genes showed that ceftazidime/avibactam-resistant KPC-Kp 
127 su-ains with wild-type blaKPc had truncated ompK35 and ompK37, and GD inse11ion at 134-135 
128 aminoacid within ompK36 and were also resistant to meropenem/vaborbactam (Table 1). At the 
129 same time, ceftazidime/avibactam-resistant KPC-Kp su-ain with mutated KPC (i.e. KpBO5) had 
130 wild type ompK36 gene (Table 1). 
131 Examination of plasmid content showed that ceftazidime/avibactam-resistant KPC-Kp strains 
132 canied similar plasmid replicon types (i.e. fucFIB (K), fucFIB, fucX3, ColRNAI), while only 
133 KpBO7 possessed additional plasmid replicon types [fucFII(K), Col(BS512) fucFIB (pQIL)]. 
134 Relative quantification analysis of blaKPC gene demonstrnted that copy number of porin-deficient 
135 KpBO3 and KpBO7 strains were 2.5- and 1.5-fold higher rather than KPC-mutated KpBO5 
136 isolates. 
137 The phylogenetic tree of the KCP-Kp genomes showed KpBO3 and KpBO7 clustered closely and 
138 fo1med a monophyletic group with KPC-Kp 27318 strain (Figure Sl in the Supplementruy 
139 Material). At the same time, KPC-Kp strain (e.g. KpBO5) hru·bouring D179Y mutation within 
140 blaKPc-2 gene belongs to a different clade, thus suggesting no clonal relationship. 
141 
142 Discussion 
143 Here we described the emergence of resistant KPC-Kp strains isolated from patients with BSI and 
144 no histo1y of previous antimicrobial exposure to ceftazidime/avibactam treatment. Our results 
145 showed that resistance was associated to porins ompK35-ompK37 deficiency associated with an 
146 ompK36 variant in two out of three ceftazidime/avibactam-resistant KPC-Kp strains. futerestingly, 
147 porins deficiency was also related to meropenem/vaborbactam resistance while no others 
148 mechanisms or mutations were found (i.e. IS5 inse1tion in the ompK36 gene promoter region) [11]. 
149 At the same time, only one KPC-Kp strain resistant to ceftazidime/avibactam exhibited a specific 
150 mutation within blaKPc gene (e.g. Dl 79Y). Similar finding was observed in a cru·bapenem-
151 susceptible ST307 KPC-Kp strain harboring mutated blaKPc-2 gene that emerged during 
152 ceftazidime/avibactam treatment [12]. Although we observed a similar mutation, our original 
153 assembly gave wild type blaKPc-2 and only successive reads alignment demonstrated the presence of 
154 a mixed subpopulations harboring wild-type and polymo1phic gene. These results are in accordance 
155 with our previously findings [5] that demonstrated as two distinct subpopulations within a single 
156 isolate determine a hybrid phenotype which result resistant both to carbapenems and 
15 7 ceftazidime/ avibactam. 
158 Phylogenetic analysis demonstrnted that porins-deficient KPC-Kp strains were closely related and 
159 segregated into a monophyletic group with a blaKPc-3�canying KPC-Kp strain recently described 
160 [13]. 
161 We observed that none of three patients with BSI due to resistant KPC-Kp strains emerged 
162 following ceftazidime/avibactam-based ti·eatment. Although these findings seem to be reliable for 
163 porins-deficient strains it was doubtful for mutated-KPC strain. Therefore, considering the high 
164 incidence of KPC-Kp sti·ains in our counti·y, it was plausible that patient acquired mutated-blaKPc-2 
165 during hospitalization and that mixed subpopulations emerged during colonization. Previous studies 
166 demonsti·ated that mechanisms responsible to resistance includes specific mutations within blaKPc 
167 gene and that emerged after ceftazidime/avibactam ti·eatment or hyperexpression of blaKPc gene 
168 associated with porins loss with no previously exposure to ceftazidime-avibactam [3-8,12]. 
169 A limitation of this study is that the expression of bla'KPc gene was not detennined in CAZ/AVI-
170 resistant strains. However, our results demonstrated that an increased KPC copy number was 
171 associated to CAZ/A VI resistance in porin-deficient KPC-Kp sti·ains. 
172 In conclusion, our data described the emergence of ceftazidime/avibactam-resistance in a country 
173 endemic for KPC-Kp, reinforce the role of rectal CPE screening to prevent spreading of 
174 ceftazidime/avibactam resistant strains and highlight the importance of susceptibility testing of 
175 these new molecules. 
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242 Figure 1. Distribution of ceftazidime/avibactam MICs of KPC-producing K. pneumoniae strains 
243 isolated from bacteremic patients included in this study. Dotted line represents the trend line 
244 
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Abbreviations: ETP, Ertapenem; IPM, imipenem; MEM, meropenem; CRO, ceftriaxone; CAZ/A VI, ceftazidime/avibactam; MER/V AB, meropenem/vaborbactam GEN, gentamicin; AMK, amikacin; TGC, tigecycline; 
ST, sequence type; WT, wild type; BSI, bloodstream infection. 
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